SCHEMBL575956

SCHEMBL575956

Fc1ccccc1Sc1ccccc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 1/20 0.52
PGR P06401 1/20 0.42
AR P10275 1/20 0.42
ACHE P22303 1/20 0.41
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
APOBEC3A P31941 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40
APOBEC3G Q9HC16 1/20 0.40
NOTUM Q6P988 1/20 0.40
LDHA P00338 1/20 0.40
NFE2L2 Q16236 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
PTGS2 P35354 1/20 0.37
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
PTPN11 Q06124 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11124289 0.85 HAO1 (0.43) HAO1PGRARLMNAGAA
SCHEMBL21148523 0.85 HAO1 (0.43) HAO1PGRARACHELMNA
SCHEMBL2154630 0.85 HAO1 (0.43) HAO1PGRARACHELMNA
SCHEMBL30567146 0.85 MEN1 (0.52) HAO1LMNAAPOBEC3G
SCHEMBL2154633 0.85 ACHE (0.54) HAO1PGRARACHELMNA
SCHEMBL1341376 0.85 MEN1 (0.52) HAO1LMNAAPOBEC3G
SCHEMBL777473 0.84 HAO1 (0.46) HAO1PGRARLDHA
SCHEMBL29722885 0.84 HAO1 (0.46) HAO1PGRARLDHA
SCHEMBL576534 0.81 APOBEC3G (0.46) HAO1PGRARACHEAPOBEC3G
SCHEMBL30963098 0.81 APOBEC3G (0.46) HAO1PGRARACHEAPOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210252484-A1 SELECTIVE HYDROGENATION CATALYST, PREPARATION METHOD AND APPLICATION THEREOF ZHEJIANG UNIVERSITY (CN) 2021-08-19 US claimed
WO-2025076387-A1 MULTIBLOCK COPOLYMERS FOR MOISTURE SWING DIRECT AIR CAPTURE ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2025-04-10 WO disclosed
US-12100809-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-24 US disclosed
US-20240297344-A1 NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-05 US disclosed
CN-115911573-A Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same 三菱化学株式会社 2023-04-04 CN disclosed
US-11616253-B2 Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2023-03-28 US disclosed
US-20220278370-A1 NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2022-09-01 US disclosed
CN-112174862-B Synthesis method of benzyl sulfide 成都理工大学 2022-07-12 CN disclosed
US-11367899-B2 Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2022-06-21 US disclosed
US-20220149436-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2022-05-12 US disclosed
EP-1361880-A2 6-SUBSTITUTED PYRIDO-PYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 2003-11-19 EP disclosed
US-20030171584-A1 Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. SYNTEX (U.S.A.) LLC 2003-09-11 US disclosed
US-6558276-B1 Improved feeling without impairing intrinsic resilience; core made from rubber composition of a base rubber, an organic peroxide, an alpha, beta unsaturated carboxylic acid, and a bis type halogen-substituted phenyl disulfide SUMITOMO RUBBER INDUSTRIES LIMITED (JP) 2003-05-06 US disclosed
WO-2002064594-A2 6-SUBSTITUTED PYRIDO-PYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 2002-08-22 WO disclosed
US-6242654-B1 REACTING A PHENOLATE COMPOUND WITH AN ORGANIC FLUORINATING AGENT TO PREPARE A FLUORINE SUBSTITUTED AROMATIC COMPOUND MITSUI CHEMICALS, INC. (JP) 2001-06-05 US disclosed
US-6241625-B1 A GOLF BALL COMPRISING A COVER MEMBER AND A CORE MEMBER, WHEREIN POLYAMIDE, TERPOLYMER IONOMER CONTAINING ETHYLENE, (METH)ACRYLIC ACID, AND (METH)ACRYLIC ESTER MIXTURES WITH PEROXIDE AND SULFIDE SUMITOMO RUBBER INDUSTRIES, LTD. (JP) 2001-06-05 US disclosed
EP-1013629-A1 Preparation process of fluorine subsituted aromatic compound Mitsui Chemicals, Inc. (JP) 2000-06-28 EP disclosed
US-5250657-A Process for preparing polyarylene thioether SEISAN KAIHATSU KAGAKU KENKYUSHO (JP) 1993-10-05 US disclosed
EP-0440106-A2 Process for preparing polyarylene thioethers SEISAN KAIHATSU KAGAKU KENKYUSHO (JP) 1991-08-07 EP disclosed
US-4339611-A BUTANOL, BUTANAL, COBALT, IODINE GULF RESEARCH & DEVELOPMENT COMPANY (US) 1982-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210252484-A1 SELECTIVE HYDROGENATION CATALYST, PREPARATION METHOD AND APPLICATION THEREOF HSDL2, HSD17B2, HSD3B2 HAO1 52/4885PGR 260/4885AR 73/4885
US-20030171584-A1 Treating p38 mediated disorders such as arthritis, Crohns disease, irritable bowel syndrome adult respiratory distress syndrome or chronic obstructive pulmonary disease. ARRB1, MAPK1, MAPK8 HAO1 1717/4885PGR 3885/4885AR 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.